ZIMMERMANN HOLGER
No ORCID on file
· 450 papers in corpus
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …